Thursday, July 2nd, 2015
Global bio-pharma giant AstraZeneca and the University of Adelaide have today announced an exciting new collaboration which will see 50 of AstraZeneca’s drug compounds passed to university researchers to study new therapies.

In return for first rights for AstraZeneca to commercialise any discovery that university researchers make, the university will have access to compounds in several therapy areas, such as cardiovascular, metabolic, respiratory, oncology, autoimmune and infection, and neuroscience diseases.

The collaboration is based on AstraZeneca’s Open Innovation platform, which takes its new and existing drug compounds out of AstraZeneca’s laboratories and into the hands of research centres around the world.

Adelaide Research and Innovation (ARI), the University of Adelaide’s commercialisation arm, sealed the agreement which is a first for South Australia.

“This is an extremely exciting opportunity for researchers at the University of Adelaide to collaborate with the industry-leading scientists at AstraZeneca to develop new medicines,†said Dr Jane Rathjen, ARI Deputy Director. “It’s a win-win situation plus the community
stands to benefit from potential new drugs.

“This partnership will allow for access to optimised compounds, technologies, multi-disciplinary science, services and know-how to speed up research outcomes, and most importantly the opportunity to see ideas develop into treatments for patients,†she says.

AstraZeneca and ARI will also agree to fund successful research proposals that result from the partnership which have the potential to expand the reputation of the University of Adelaide and South Australia as a centre for medical research excellence.

Paul Spittle, Company President for AstraZeneca Australia, said, “Furthering the boundaries of science is at the core of what AstraZeneca does, so we’re absolutely delighted to be supporting University of Adelaide researchers who have the potential to find exciting new developments in medicine thanks to this collaboration.â€

Notes to Editors

AstraZeneca Open Innovation
The AstraZeneca Open Innovation platform has been created to help identify and establish mutually beneficial collaborations that will lead to the discovery and development of new medicines. It provides a robust but simple process for AstraZeneca to link their expertise, experience, resources, and technology with those of external experts and to explore prospective partnerships that accelerate the advancement of medical science and breakthrough therapies for patients. Visit AstraZeneca’s Open Innovation website to lean more:

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

About Adelaide Research & Innovation (ARI)
Adelaide Research & Innovation Pty Ltd is wholly owned by the University of Adelaide and is responsible for managing all IP commercialisation, contract research and consulting activity. Operating for over 30 years, ARI’s role is to match business and government needs with research and innovation to produce better results. For more information visit:

About the University of Australia
The University of Adelaide is one of Australia’s leading research-intensive universities and is consistently ranked among the top 1% of universities in the world. Established in 1874, it is Australia’s third oldest university with a strong reputation for research and teaching excellence, and producing graduates that make an impact on the world.

Please see attached Appendix 1: Pre-clinical and clinical compounds ARI/AZ Open Innovation Collaboration list

Media Contact:

Kate Bourne
Media and Communications Officer
The University of Adelaide
Phone: +61 8 8313 3173
Mobile: +61 (0)457 537 677

Robert Gunning
Head of Corporate Communications
AstraZeneca Australia
Phone : +61 2 9856 8108
Mobile : +61 (0)410 589 126

Contact Profile


NewsMaker is an Australian Press Release Distribution and Social Media Marketing service founded in 2004. The company today represents over 22,000 brands who seek to share their content with journalists, bloggers and the community.

Newsmaker Editors
P: +61 414 69 70 71


research collaboration set aid drug discovery



More Formats

View QR Code